KLOW

Fujian Lumira Biotech Co., Ltd. (operating as Fujian Yaoguang Biotechnology Co., Ltd.) is an innovative AI+CRDMO enterprise specializing in peptides and oligonucleotides, covering the full industrial chain from intermediates and APIs to finished formulations. The company has mastered complete process technologies for blockbuster GLP-1 drugs including semaglutide, tirzepatide, and retatrutide, with ton-scale-and-above annual synthesis and purification capacity, and is building a pilot-scale production base in the Quanzhou South Wing New Area within the Quanzhou-Xiamen-Kinmen Life and Health Silicon Valley, aiming to combine AI-driven R&D with embodied-robotics manufacturing as part of China's 'Jinjiang Peptide & Nucleic Acid Valley' initiative. Based in Jinjiang City, Quanzhou, Fujian Province, the company sells its active pharmaceutical ingredients, intermediates, and bio products worldwide, and is recognized for its brand, experienced R&D personnel, delivery speed, production capacity, rich product line, and accommodation of buyer specifications and small orders with high-quality service.